RecruitingPHASE1, PHASE2NCT06873100
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Studying Relapsing polychondritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University People's Hospital
- Principal Investigator
- Zhanguo LiPeking University Institute of Rheuamotology and Immunology
- Intervention
- Upadacitinib(drug)
- Enrollment
- 30 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06873100 on ClinicalTrials.govOther trials for Relapsing polychondritis
Additional recruiting or active studies for the same condition.